BloggingStocks http://www.bloggingstocks.com BloggingStocks http://www.blogsmithmedia.com/http://www.bloggingstocks.com/media/feedlogo.gif BloggingStocks http://www.bloggingstocks.com en-us Copyright 2012 Weblogs, Inc. The contents of this feed are available for non-commercial use only. Blogsmith http://www.blogsmith.com/<![CDATA[A 'Fool-Proof' Retirement Plan for 20-Year-Olds]]>http://www.bloggingstocks.com/2011/03/07/a-fool-proof-retirement-plan-for-20-year-olds/http://www.bloggingstocks.com/2011/03/07/a-fool-proof-retirement-plan-for-20-year-olds/http://www.bloggingstocks.com/2011/03/07/a-fool-proof-retirement-plan-for-20-year-olds/#commentsFiled under: , , ,

"I've put together a retirement blue print that will allow anyone who is 20 years old or younger to retire a multi-millionaire," says Steve Christ.

The editor of The Wealth Advisory explains, "This diversified portfolio, contains a transport, a utility, a tech company, a health care giant, and a defense contractor, all of which pay nice steady dividends with room for growth.

"All you need to start is $15,000 initial investment to go along with an additional $100 bucks a week in total contributions divided among the five stocks.

Continue reading A 'Fool-Proof' Retirement Plan for 20-Year-Olds

A 'Fool-Proof' Retirement Plan for 20-Year-Olds originally appeared on BloggingStocks on Mon, 07 Mar 2011 11:00:00 EST. Please see our terms for use of feeds.

Permalink | Email this | Comments]]>Abbott Laboratoriesabtdukduke energyfeaturedintcIntelLMTNorfolkSouthernnscretirement portfoliosteve christsteven halpernStevenHalpernthestockadvisors.comwealth advisoryMon, 07 Mar 2011 11:00:00 EST<![CDATA[Abbott (ABT) and Baxter (BAX): Healthy Gains]]>http://www.bloggingstocks.com/2011/03/01/abbott-abt-and-baxter-bax-healthy-gains/http://www.bloggingstocks.com/2011/03/01/abbott-abt-and-baxter-bax-healthy-gains/http://www.bloggingstocks.com/2011/03/01/abbott-abt-and-baxter-bax-healthy-gains/#commentsFiled under: , , ,

"We follow an approach to investng that focuses on broadly diversified investments in undervalued stocks for their long-term appreciation potential," says value investor John Buckingham.

The money manager and editor of The Prudent Speculator explains, " Two recently featured ideas -- Abbott Laboratories (ABT) and Baxter International (BAX) -- are among those we feel could serve as a portfolio foundation or as a new ideas for well- diversified holdings.

Continue reading Abbott (ABT) and Baxter (BAX): Healthy Gains

Abbott (ABT) and Baxter (BAX): Healthy Gains originally appeared on BloggingStocks on Tue, 01 Mar 2011 10:00:00 EST. Please see our terms for use of feeds.

Permalink | Email this | Comments]]>Abbott LaboratoriesabtBaxbaxter internationalBaxterInternationaldrug stocksDrugStocksfeaturedhealthcare stocksjohn buckinghamprudent speculatorPrudentSpeculatorsteven halpernthestokadvisors.comTue, 01 Mar 2011 10:00:00 EST<![CDATA[The Timely 10: Best Blue Chip Dividend Buys]]>http://www.bloggingstocks.com/2011/01/28/the-timely-10-iq-trends-best-blue-chip-buys/http://www.bloggingstocks.com/2011/01/28/the-timely-10-iq-trends-best-blue-chip-buys/http://www.bloggingstocks.com/2011/01/28/the-timely-10-iq-trends-best-blue-chip-buys/#commentsFiled under: , , , , , , , , , , , ,

AT&T logo"High-quality stocks bought at historically low-price-to-high-yield offer the best potential for downside protection and upside appreciation," says dividend specialist Kelley Wright.

The editor of IQ Trends explains, "Our 'Timely Ten' list is our reasoned expectation based on our methodology and experience for what we believe will perform best over the next five years.

"Our 'Timely Ten' list is our reasoned expectation based on our methodology and experience for what we believe will perform best over the next five years. Do we believe that all 10 will go up simultaneously or immediately? Of course not.

Continue reading The Timely 10: Best Blue Chip Dividend Buys

The Timely 10: Best Blue Chip Dividend Buys originally appeared on BloggingStocks on Fri, 28 Jan 2011 10:00:00 EST. Please see our terms for use of feeds.

Permalink | Email this | Comments]]>Abbott Laboratoriesabtaltria groupattblue chip stockscoca-coladividend stocksEXCExelonfeaturedincome stocksinvestment quality trendsiq trendsjnjjohnson and johnsonkelley wrightkomomolson coorspepPepsicopgprocter and gamblesteven halperntapthestockadvisors.comunited technologiesutxyield stocksFri, 28 Jan 2011 10:00:00 EST<![CDATA[Abbott Labs (ABT): A Rich Pipeline in Pharma]]>http://www.bloggingstocks.com/2010/12/01/abbott-labs-abt-a-rich-pipeline-in-pharma/http://www.bloggingstocks.com/2010/12/01/abbott-labs-abt-a-rich-pipeline-in-pharma/http://www.bloggingstocks.com/2010/12/01/abbott-labs-abt-a-rich-pipeline-in-pharma/#comments"Because major U.S. pharmaceutical companies face patent expirations on blockbuster drugs, consensus earnings expectations for the group are modest," says Richard Moroney.

The editor of Dow Theory Forecasts explains, "One exception is Abbott Laboratories (ABT); Wall Street expects to increase earnings at a 10% annual rate over the next five years.

"Yet the market appears to discount that outlook, and the stock's price/earnings-to-growth ratio (PEG) of 1.2 is well below its peers.

Continue reading Abbott Labs (ABT): A Rich Pipeline in Pharma

Abbott Labs (ABT): A Rich Pipeline in Pharma originally appeared on BloggingStocks on Wed, 01 Dec 2010 10:20:00 EST. Please see our terms for use of feeds.

Permalink | Email this | Comments]]>abbottAbbott Laboratoriesabtdow theory forecastsdrug stocksfeaturedhealthcare stockshumirapharma stockspharmaceutical stocksrichard moroneythestockadvisors.comWed, 01 Dec 2010 10:20:00 EST<![CDATA[Blue Chip Buys: The Timely Ten]]>http://www.bloggingstocks.com/2010/07/14/blue-chip-buys-the-timely-ten/http://www.bloggingstocks.com/2010/07/14/blue-chip-buys-the-timely-ten/http://www.bloggingstocks.com/2010/07/14/blue-chip-buys-the-timely-ten/#commentsKelley Wright.

The editor of Investment Quality Trends explains, "To that end we believe that high-quality stocks purchased at historically low-price-to-high-yield offers the best potential for downside protection and upside appreciation.

"The Timely Ten list of stocks is our reasoned expectation based on our methodology and experience for what we believe will perform best over the next five years.

Continue reading Blue Chip Buys: The Timely Ten

Blue Chip Buys: The Timely Ten originally appeared on BloggingStocks on Wed, 14 Jul 2010 13:20:00 EST. Please see our terms for use of feeds.

Permalink | Email this | Comments]]>Abbott Laboratoriesabtadpautomatic data processingblue chip stockscoca-colacvxdividendsExxonMobilincome stocksinvestment quality trendsiq trendsjnjjohnson and johnsonkomcdmcdonaldspeppgpmprocter and gamblesteven halpernthestockadvisors.comxomyield stocksWed, 14 Jul 2010 13:20:00 EST<![CDATA[AstraZeneca and Abbott Labs Receive FDA Response]]>http://www.bloggingstocks.com/2010/03/30/astrazeneca-and-abbott-labs-receive-fda-response/http://www.bloggingstocks.com/2010/03/30/astrazeneca-and-abbott-labs-receive-fda-response/http://www.bloggingstocks.com/2010/03/30/astrazeneca-and-abbott-labs-receive-fda-response/#commentsFiled under:

AstraZeneca (AZN) and Abbott Laboratories (ABT) announced this morning they received a complete response letter from the Food and Drug Administration regarding their new drug application for Certriad capsules. The FDA requested more information. The companies stated that they are currently evaluating the FDA's letter and will continue discussions with the agency to see what the next step will be with the drug. AZN and ABT will then respond to the FDA's request for further information.

Certriad is for the treatment of mixed dyslipidemia, a combination of two or more lipid abnormalities including the "bad" cholesterol (LDL), high triglycerides, and low "good" cholesterol (HDL). The active ingredients in Certirad are Crestor and Trilipix from ABT and AZN.

Continue reading AstraZeneca and Abbott Labs Receive FDA Response

AstraZeneca and Abbott Labs Receive FDA Response originally appeared on BloggingStocks on Tue, 30 Mar 2010 10:00:00 EST. Please see our terms for use of feeds.

Permalink | Email this | Comments]]>Abbott LaboratoriesABTAstraZenecaazncholesterolcholesterol drugsFDAfeaturedinthenewsTue, 30 Mar 2010 10:00:00 EST<![CDATA[Analyst Calls: ABT, ARO, BMY, CELG, DNDN, FACT, GS, PSUN, SCCO, ULTI ...]]>http://www.bloggingstocks.com/2010/03/12/analyst-calls/http://www.bloggingstocks.com/2010/03/12/analyst-calls/http://www.bloggingstocks.com/2010/03/12/analyst-calls/#commentsFiled under: , , , , , ,

Analyst Upgrades

  • Deutsche Bank upgraded Southern Copper (SCCO) to buy from hold to reflect valuation and positive near-term catalysts. The firm raised its target for shares to $38 from $35.
  • JMP Securities upgraded Ultimate Software (ULTI) to outperform from market perform. The firm cites the company's expanding employee base for the upgrade. The firm has a $40 target on the stock.
  • Piper Jaffray upgraded Aeropostale (ARO) to neutral from underweight following the company's Q4 results and raised its target for shares to $31 from $24.
  • Kennametal (KMT) was upgraded to sell from conviction sell at Goldman.
  • Lifetime Brands (LCUT) was upgraded to outperform from market perform at Barrington.
  • Volvo (VOLVY) was upgraded to overweight from underweight at JPMorgan.

Continue reading Analyst Calls: ABT, ARO, BMY, CELG, DNDN, FACT, GS, PSUN, SCCO, ULTI ...

Analyst Calls: ABT, ARO, BMY, CELG, DNDN, FACT, GS, PSUN, SCCO, ULTI ... originally appeared on BloggingStocks on Fri, 12 Mar 2010 11:00:00 EST. Please see our terms for use of feeds.

Permalink | Email this | Comments]]>AbbottAbbott LaboratoriesAbbott LabsABTAeropostaleAROBMYBristol MyersCELGCelgeneClearwater PaperCLWDendreonDNDNdowngradesFacet BiotechFACTGILDGileadGoldman SachsGrand CanyonGSHBCHSBCHSBC HoldingsinitiationsinthenewsKennametalKMTLCUTLifetime BrandsLOPENRGNRG EnergyPacific SunwearProvengePSUNSCCOSGISilicon GraphicsSouthern CopperULTIUltimate SoftwareVolvoVOLVYFri, 12 Mar 2010 11:00:00 EST<![CDATA[Abbott Labs wishes upon a StarLIMS]]>http://www.bloggingstocks.com/2009/12/15/abbott-labs-wishes-upon-a-starlims/http://www.bloggingstocks.com/2009/12/15/abbott-labs-wishes-upon-a-starlims/http://www.bloggingstocks.com/2009/12/15/abbott-labs-wishes-upon-a-starlims/#commentsFiled under: ,

Bright and early this morning, lab-technology innovator StarLIMS (LIMS) announced that it will be bought by pharmaceutical firm Abbott Laboratories (ABT) for roughly $123 million. This purchase price reflects a per-share price tag of $14 for LIMS, which closed Monday's trading session near the $10 region.

Needless to say, LIMS was the subject of heavy pre-market trading, which pushed the per-share price closer to the premium paid by ABT. According to the report, ABT will acquire all outstanding equity of LIMS, which currently has roughly $18 million cash in hand.

Continue reading Abbott Labs wishes upon a StarLIMS

Abbott Labs wishes upon a StarLIMS originally appeared on BloggingStocks on Tue, 15 Dec 2009 10:40:00 EST. Please see our terms for use of feeds.

Permalink | Email this | Comments]]>abbott laboratoriesabtinthenewslimspharmaceuticalpharmaceuticalspurchasestarlimstakeoverTue, 15 Dec 2009 10:40:00 EST<![CDATA[Chasing Value: Ten stocks for 2010 Part 8: Making some cuts]]>http://www.bloggingstocks.com/2009/12/09/chasing-value-ten-stocks-for-2010-part-8-making-some-cuts/http://www.bloggingstocks.com/2009/12/09/chasing-value-ten-stocks-for-2010-part-8-making-some-cuts/http://www.bloggingstocks.com/2009/12/09/chasing-value-ten-stocks-for-2010-part-8-making-some-cuts/#commentsFiled under: , , , , , , , , , , , , , , ,

Today it's time to do some trimming of the fourteen stocks and four options on the contenders list. This review will prioritize the companies by price-to-book (P/B), price-to-sales (P/S) and return-on-equity (ROE). This does not preclude more possible stocks being added and the final list will not be done until the end of the month.

We will also compare recent stock prices to three-year highs to give us a relative idea where the stock floated in rosier times.

Continue reading Chasing Value: Ten stocks for 2010 Part 8: Making some cuts

Chasing Value: Ten stocks for 2010 Part 8: Making some cuts originally appeared on BloggingStocks on Wed, 09 Dec 2009 13:30:00 EST. Please see our terms for use of feeds.

Permalink | Email this | Comments]]>AAUKYabbott laboratoriesAbbottLaboratoriesABTAEOamerican eagle outfittersAmericanEagleOutfittersanadarko petroleumAnadarkoPetroleumanglo americanAngloAmericanAPCberkshire hathawayBerkshireHathawaybf.abrasil telecomBrasilTelecombrk.bbrown-formanBTMchasing valueChasingValueDEdeere and co.DeereAndCo.DEOdiageoe-tradeETFCezcorpEZPWFfeaturedFordGBEGEgeneral electricGeneralElectricgrubb and ellisGrubbAndEllissheldon liberSheldonLibertnt postTntPostTNTTYwells fargoWellsFargoWFCWed, 09 Dec 2009 13:30:00 EST<![CDATA[Chasing Value: Ten stocks for 2010 -- Part 5]]>http://www.bloggingstocks.com/2009/11/23/chasing-value-ten-stocks-for-2010-part-5/http://www.bloggingstocks.com/2009/11/23/chasing-value-ten-stocks-for-2010-part-5/http://www.bloggingstocks.com/2009/11/23/chasing-value-ten-stocks-for-2010-part-5/#commentsFiled under: , , ,

The march toward year end continues as three more stocks are reviewed in a search for the eventual 2010 stock picks. This year there will be nine stocks with a new wrinkle, I will add one naked put.

These options have contributed to a mind-boggling return on my 2009 portfolio, exceeding 200% to date. This has been a very unusual year, and I bet against the rampant fear in the market. I will not pretend for a moment that this is repeatable. What I will do is share my opinions and investing adventure, hoping to stimulate investor interest and dialog.

Continue reading Chasing Value: Ten stocks for 2010 -- Part 5

Chasing Value: Ten stocks for 2010 -- Part 5 originally appeared on BloggingStocks on Mon, 23 Nov 2009 13:00:00 EST. Please see our terms for use of feeds.

Permalink | Email this | Comments]]>2010abbott laboratoriesABTchasing valuemicrosoftMSFTsheldon liberTUPtupperware brandsMon, 23 Nov 2009 13:00:00 EST<![CDATA[Abbott Laboratories posts solid earnings results]]>http://www.bloggingstocks.com/2009/10/14/abbott-laboratories-posts-solid-earnings-results/http://www.bloggingstocks.com/2009/10/14/abbott-laboratories-posts-solid-earnings-results/http://www.bloggingstocks.com/2009/10/14/abbott-laboratories-posts-solid-earnings-results/#commentsFiled under: , ,

Plenty of companies are reporting earnings this Wednesday morning, one of which is Abbott Laboratories (NYSE: ABT).

The health-care giant reported third-quarter earnings of 95 cents per share, far better than last year's 69 cents per share. Taking items out of the equation, Abbott would have earned 92 cents per share, which is two cents better than the consensus estimate. Quarterly revenue matched the consensus estimate for $7.76 billion.

Continue reading Abbott Laboratories posts solid earnings results

Abbott Laboratories posts solid earnings results originally appeared on BloggingStocks on Wed, 14 Oct 2009 12:00:00 EST. Please see our terms for use of feeds.

Permalink | Email this | Comments]]>Abbott LaboratoriesABTearningsforecastHumirainthenewspharmaceuticalsWed, 14 Oct 2009 12:00:00 EST<![CDATA[Earnings preview: Abbott Labs Q3 acquisitions to pay off?]]>http://www.bloggingstocks.com/2009/10/13/earnings-preview-abbott-labs-q3-acquisitions-to-pay-off/http://www.bloggingstocks.com/2009/10/13/earnings-preview-abbott-labs-q3-acquisitions-to-pay-off/http://www.bloggingstocks.com/2009/10/13/earnings-preview-abbott-labs-q3-acquisitions-to-pay-off/#commentsFiled under: , ,

Abbott Laboratories (NYSE: ABT), the broad-based health care company that produces both Humira and Similac, is scheduled to discuss its third quarter 2009 financial results in a conference call Wednesday at 9:00 AM ET. You can catch the live webcast on the company's website.

During the three months that ended in September, Abbott Labs announced acquisitions of Visiogen, Evalve, and Solvay pharmaceuticals, as well as declared its 343rd consecutive quarterly dividend. Analysts surveyed by Thomson Reuters expect this suburban Chicago company to report that earnings rose 12.2% from a year ago to $0.90 per share. Sales for the quarter are expected to be 3.3% higher to $7.8 billion.

Continue reading Earnings preview: Abbott Labs Q3 acquisitions to pay off?

Earnings preview: Abbott Labs Q3 acquisitions to pay off? originally appeared on BloggingStocks on Tue, 13 Oct 2009 17:15:00 EST. Please see our terms for use of feeds.

Permalink | Email this | Comments]]>Abbott LaboratoriesABTearningsEvalveMerckMRKSolvayVisiogenTue, 13 Oct 2009 17:15:00 EST<![CDATA[Serious Money: Five more high yield, safe, diversified stocks -- Part 2]]>http://www.bloggingstocks.com/2009/07/14/serious-money-five-more-high-yield-safe-diversified-stocks/http://www.bloggingstocks.com/2009/07/14/serious-money-five-more-high-yield-safe-diversified-stocks/http://www.bloggingstocks.com/2009/07/14/serious-money-five-more-high-yield-safe-diversified-stocks/#commentsFiled under: , , , , , , , , , , ,

The market may be entering a more volatile period or it may just go sideways for a while. The last few weeks the market has been down. Maybe it is because the rapid rise mid-March through mid-June is forcing people to stop and take a breath, or perhaps it is because investors are having second thoughts about whether the "green shoots" Ben Bernanke spoke of in regards to a healing economy were really just weeds.

All in all, I still believe that there is opportunity in this market and I have been trying to point out how investors can get in with as little risk as possible, while being rewarded for their patience now, and when a recovery ensues ---- whenever that is. To this end, two weeks ago I posted Serious Money: Five high-yield, safe, diversified stocks and decided to follow up with another five I think will produce similar results.

Continue reading Serious Money: Five more high yield, safe, diversified stocks -- Part 2

Serious Money: Five more high yield, safe, diversified stocks -- Part 2 originally appeared on BloggingStocks on Tue, 14 Jul 2009 13:00:00 EST. Please see our terms for use of feeds.

Permalink | Email this | Comments]]>abbott laboratoriesAbbottLaboratoriesABTADPautomatic data processingAutomaticDataProcessingconocophillipsCOPDEOdiageodividendsDUKDuke EnergyDukeEnergyfeaturedgreenn shootsGreennShootssafe stocksSafeStocksserious moneySeriousMoneySheldon LiberSheldonLiberTue, 14 Jul 2009 13:00:00 EST<![CDATA[Tech talk from MarketWatch]]>http://www.bloggingstocks.com/2009/06/25/tech-talk-from-marketwatch/http://www.bloggingstocks.com/2009/06/25/tech-talk-from-marketwatch/http://www.bloggingstocks.com/2009/06/25/tech-talk-from-marketwatch/#commentsFiled under: , , , , ,

"Stocks are likely in a new downtrend," says Michael Ashbaugh. In Marketwatch's The Technical Indicator, he looks at the S&P's prospects and some drug stocks set to buck the trend.

"The S&P 500 has violated its major moving averages in the closely tracked 900 area. The recent downturn was convincingly bearish, placing the burden on market bulls to reassert the uptrend.

"After finding resistance in the 923 area, the S&P sold off sharply, edging back under its 200-day moving average, which currently holds at 900 and now marks resistance. This is bearish price action.

Continue reading Tech talk from MarketWatch

Tech talk from MarketWatch originally appeared on BloggingStocks on Thu, 25 Jun 2009 11:00:00 EST. Please see our terms for use of feeds.

Permalink | Email this | Comments]]>abbott laboratoriesabtdrug stocksglaxosmithklinegskmarketwatch technical indicatormichael ashbaughpharma stockspharmaceutical stockssteven halperntechnical stockstevateva pharmaceuticalsthestockadvisors.comThu, 25 Jun 2009 11:00:00 EST<![CDATA[Abbott (ABT): An 'income machine']]>http://www.bloggingstocks.com/2009/04/14/abbott-abt-an-income-machine/http://www.bloggingstocks.com/2009/04/14/abbott-abt-an-income-machine/http://www.bloggingstocks.com/2009/04/14/abbott-abt-an-income-machine/#commentsFiled under: , ,

"Abbott Laboratories (NYSE: ABT) is continuing its long record of rewarding shareholders," notes Alex Kolb In Zacks Elite, pointing to its 341st consecutive quarter of dividends since 1924.

"Abbott is a global, broad-based health care company that develops, manufactures and markets pharmaceuticals and medical products, including nutritionals, devices and diagnostics.

"The company employs more than 68,000 people and markets its products in more than 130 countries.

"The company recently released new data, showing that a combination of its new TriLipix triglycerides medicine and a low dose of AstraZeneca's Crestor cholesterol drug are better than the individual pills for treating heart problems.

Continue reading Abbott (ABT): An 'income machine'

Abbott (ABT): An 'income machine' originally appeared on BloggingStocks on Tue, 14 Apr 2009 10:30:00 EST. Please see our terms for use of feeds.

Permalink | Email this | Comments]]>abbott laboratoriesabbott labsAbbottLabsabtadvanced medical opticsAdvancedMedicalOpticsalex kolbAlexKolbcholesterol drugscrestordrug stocksDrugStocksfeaturedhealthcare stocksmedical stocksMedicalStockspharma stockspharmaceutical stocksPharmaceuticalStockszacks eliteZacksEliteTue, 14 Apr 2009 10:30:00 EST<![CDATA[Abbott Labs (ABT) gains on stent study results]]>http://www.bloggingstocks.com/2009/03/30/abbott-labs-abt-gains-on-stent-study-results/http://www.bloggingstocks.com/2009/03/30/abbott-labs-abt-gains-on-stent-study-results/http://www.bloggingstocks.com/2009/03/30/abbott-labs-abt-gains-on-stent-study-results/#commentsFiled under: , , , ,

ABT logoAbbott Laboratories (NYSE: ABT - option chain) shares are higher today despite the surrounding market meltdown after a study released over the weekend showed the company's Xience stent showed significant safety advantages over competitor Boston Scientific's (NYSE: BSX) Taxus stent. If you think that the stock won't fall by too much in the coming months, then now could be a good time to look at a bullish hedged trade on ABT.

ABT opened this morning at $46.69. So far today the stock has hit a low of $46.65 and a high of $47.90. As of 11:35, ABT is trading at $47.73, up $1.13 (2.4%). The chart for ABT looks bullish and S&P gives ABT a positive 5 STARS (out of 5) strong buy ranking.

Continue reading Abbott Labs (ABT) gains on stent study results

Abbott Labs (ABT) gains on stent study results originally appeared on BloggingStocks on Mon, 30 Mar 2009 12:20:00 EST. Please see our terms for use of feeds.

Permalink | Email this | Comments]]>abbott laboratoriesAbbottLaboratoriesABTboston scientificBostonScientificBSXinthenewsinvestors observerInvestorsObserveroptionsstentMon, 30 Mar 2009 12:20:00 EST<![CDATA[Abbott (ABT): Contrarian sees healthy gains]]>http://www.bloggingstocks.com/2009/01/30/abbott-abt-contrarian-sees-healthy-gains/http://www.bloggingstocks.com/2009/01/30/abbott-abt-contrarian-sees-healthy-gains/http://www.bloggingstocks.com/2009/01/30/abbott-abt-contrarian-sees-healthy-gains/#commentsFiled under: , ,

"I think 2009 will be a very tough year for the economy but an exceptional year for stocks," says Alexander Green of The Oxford Club. Here, he looks at Abbott Laboratories (NYSE: ABT).

"The company has been around for more than 120 years. It currently operates in more than 130 countries, selling hundreds of products, including Ultane (an inhaled anesthetic), the anti-infective Biaxin XL, and TriCor and Niaspan to manage cholesterol.

"However, Abbott's biggest growth driver is Humira, a blockbuster drug that targets autoimmune disorders. The drug has received FDA approval to treat a number of diseases, including rheumatoid arthritis, psoriasis and Crohn's disease.

Continue reading Abbott (ABT): Contrarian sees healthy gains

Abbott (ABT): Contrarian sees healthy gains originally appeared on BloggingStocks on Fri, 30 Jan 2009 12:30:00 EST. Please see our terms for use of feeds.

Permalink | Email this | Comments]]>abbottabbott laboratoriesabtalex greendrug stockshealth stockshealthcare stocksHealthcareStocksmedical stocksMedicalStocksoxford clubOxfordClubpharmaceuticalsthestockadvisors.comFri, 30 Jan 2009 12:30:00 EST<![CDATA[Best stocks to retire on from Fortune 40]]>http://www.bloggingstocks.com/2008/06/12/best-stocks-to-retire-on-from-fortune-40/http://www.bloggingstocks.com/2008/06/12/best-stocks-to-retire-on-from-fortune-40/http://www.bloggingstocks.com/2008/06/12/best-stocks-to-retire-on-from-fortune-40/#commentsFiled under: , , , , , , , , , ,

Many of us would be happy to benefit from a quiet retirement without facing concerns of losing all of our hard earned money. Fortune 40 gives us a helping hand by suggesting some big names to invest in that could offer us the results that we are looking for.

One such company is Abbott Laboratories (NYSE: ABT), whose earnings surged 35% during its last quarter, helped by its famous anti-inflammatory drug Humira and HIV treatment Kaletra. Looking ahead to the company's performance, CEO Miles White is planing to keep his main attention on its medical devices unit which is seen as a key element against strong competition.

Fortune 40 also looks at beverage maker The Coca-Cola Company (NYSE: KO), which benefits from strong international gains able to beat recent weakness in U.S. In addition, it looks like the company's acquisition of Glacéau and its VitaminWater brand offer it a good support to outperform on the market.

Continue reading Best stocks to retire on from Fortune 40

Best stocks to retire on from Fortune 40 originally appeared on BloggingStocks on Thu, 12 Jun 2008 16:19:00 EST. Please see our terms for use of feeds.

Permalink | Email this | Comments]]>Abbott LaboratoriesAbbottLaboratoriesABTCisco SystemsCiscoSystemsCLCoca-ColaColgate-PalmoliveCSCOJNJJohnson JohnsonJohnsonJohnsonKOMicrosoftMSFTPGProcter GambleProcterGambleThu, 12 Jun 2008 16:19:00 EST<![CDATA[Turnaround time for drug stocks? 10 top picks]]>http://www.bloggingstocks.com/2008/06/03/turnaround-time-for-drug-stocks-10-top-picks/http://www.bloggingstocks.com/2008/06/03/turnaround-time-for-drug-stocks-10-top-picks/http://www.bloggingstocks.com/2008/06/03/turnaround-time-for-drug-stocks-10-top-picks/#commentsFiled under: , , , , , , ,

"You can invest for all the right reasons and still get the wrong result," notes long-standing turnaround stock expert George Putnam, referring to the poor performance of the pharmaceutical sector in recent years.

Here, in his industry-leading The Turnaround Letter, he offers a fascinating review of 10 leading drug stocks which he now believes offer a combination of growth potential at "pretty cheap" valuations. Here is his overview.

"In 2000 and 2001, when the Internet boom was becoming a bust, many smart investors turned away from technology stocks and put their money into drug stocks. How could you go wrong with the big pharmaceutical companies?

"Demand for their products was growing as the population aged. These companies had huge research
and development programs that seemed to keep cranking out new blockbuster drugs. And most of them had great balance sheets, with many paying handsome dividends.

"Much of this reasoning has been borne out in the intervening years. Many large drug manufacturers have rung up substantial revenue gains over the last decade. So what's happened to the big drug stocks? With few exceptions they have gone sideways or down - in some cases down a lot.

Continue reading Turnaround time for drug stocks? 10 top picks

Turnaround time for drug stocks? 10 top picks originally appeared on BloggingStocks on Tue, 03 Jun 2008 10:10:00 EST. Please see our terms for use of feeds.

Permalink | Email this | Comments]]>abbott laboratoriesabbott labsAbbottLabsabtastrazenecaaznbristol myers squibb-bmyBristolMyersSquibb-bmydrug stocksDrugStockseli lillyEliLillyfeaturedgeorge putnamglaxosmithklinegskhealth care stocksHealthCareStocksjnjjohnson johnsonllymerckmrlpfepfizerpharmaceutical stocksthestockadvisors.comturnaround letterturnaround stocksTurnaroundLetterwyewyethTue, 03 Jun 2008 10:10:00 EST<![CDATA[Abbott Labs (ABT) rises on FDA's Merck action]]>http://www.bloggingstocks.com/2008/04/29/abbott-labs-abt-rises-on-fdas-merck-action/http://www.bloggingstocks.com/2008/04/29/abbott-labs-abt-rises-on-fdas-merck-action/http://www.bloggingstocks.com/2008/04/29/abbott-labs-abt-rises-on-fdas-merck-action/#commentsFiled under: , , , , ,

ABT logoAbbott Laboratories (NYSE: ABT) shares are trading higher after the Food and Drug Administration denied regulatory approval for Merck & Co.'s (NYSE: MRK) cholesterol drug Cordaptive. The Merck drug would have directly competed with ABT's own cholesterol drug. If you think that the stock won't fall by too much in the coming months, then now could be a good time to look at a bullish hedged trade on ABT.

After hitting a one-year low of $49.58 in July, the stock hit a one-year high of $61.09 in January. ABT opened this morning at $53.32. So far today the stock has hit a low of $52.97 and a high of $53.73. As of 12:10, ABT is trading at $53.24, up $1.63 (3.2%). The chart for ABT looks bearish and steady, while S&P gives the stock a positive 4 STARS (out of 5) buy rating.

For a bullish hedged play on this stock, I would consider a June bull-put credit spread below the $50 range. A bull-put credit spread is an options position that combines the purchase and sale of put options to hedge risk in case the stock doesn't do what you think but still leverage nice returns. For this particular trade, we will make a 13.6% return in just seven weeks as long as ABT is above $50 at June expiration. Abbott would have to fall by more than 6% before we would start to lose money. Learn more about this type of trade here.

Continue reading Abbott Labs (ABT) rises on FDA's Merck action

Abbott Labs (ABT) rises on FDA's Merck action originally appeared on BloggingStocks on Tue, 29 Apr 2008 13:45:00 EST. Please see our terms for use of feeds.

Permalink | Email this | Comments]]>abbott laboratoriesAbbottLaboratoriesABTFDAinthenewsInvestors ObserverInvestorsObserverMerckMRKoptionsTue, 29 Apr 2008 13:45:00 EST